Managers’ transactions

Company Overview - BioPorto A/S is an in vitro diagnostics company focused on saving lives and improving quality of life through actionable biomarkers designed to assist clinicians in patient management [6] - The company utilizes its expertise in antibodies and assay development to create a pipeline of novel products targeting conditions with significant unmet medical needs [6] Key Products - The flagship products of BioPorto are based on the NGAL biomarker, which aids in the risk assessment and diagnosis of Acute Kidney Injury (AKI) [7] - NGAL tests allow for quicker identification of patients at risk of AKI compared to standard measurements, enabling earlier intervention and tailored patient management strategies [7] Recent Transactions - BioPorto A/S completed a directed issue, with notifications received regarding transactions related to shares made by persons in managerial positions [1] - Jens Due Olsen, Chair of the Board, subscribed to 2,984,629 new shares at a price of DKK 1.3402 on April 25, 2025 [2] - Henrik Juul, Vice Chair, subscribed to 746,157 shares at the same price on the same date [3] - Peter Mørch Eriksen, CEO, subscribed to 373,078 shares, while Niels Høy Nielsen, CFO, subscribed to 186,539 shares, both at DKK 1.3402 on April 25, 2025 [4] Company Information - BioPorto has facilities located in Copenhagen, Denmark, and Boston, MA, USA [8] - The shares of BioPorto A/S are listed on the Nasdaq Copenhagen stock exchange [8]